• On 9 December 2025, CorMedix director Steven W. Lefkowitz sold 40,000 shares of common stock for about US$475,200, leaving him with 80,498 shares, shortly after the company reported Q3 2025 earnings and revenue that significantly exceeded market forecasts.
• The combination of robust quarterly results and insider selling draws attention to how CorMedix’s recent operational momentum aligns with leadership’s portfolio decisions.
• With CorMedix’s Q3 earnings beating expectations, we’ll examine how this performance shapes the existing investment narrative built around acquisitions and pipeline growth.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

CorMedix Investment Narrative Recap

To own CorMedix, you need to believe the combined CorMedix–Melinta business can translate its expanding anti infective portfolio and recent profitability into durable cash flows, despite integration and execution risks. The latest insider sale by director Steven W. Lefkowitz, following a strong Q3 beat, does not appear to alter the key near term catalyst, which remains progress on pipeline and label expansion programs, nor does it materially change the biggest current risk around acquisition integration and debt funded growth.

Among recent announcements, CorMedix’s Q3 2025 results stand out as most relevant here, with revenue of US$104.28 million and net income of US$108.56 million sharply higher than a year earlier. That performance, together with raised guidance for 2025 pro forma revenue to US$325 million to US$350 million, frames the insider sale in the context of a company that has quickly shifted to profitability while still facing execution risk on integrating Melinta’s assets and scaling its anti infective franchise.

Yet alongside the strong Q3 and rising guidance, investors should be aware that the sizeable Melinta acquisition and new debt load could...

CorMedix's narrative projects $433.6 million revenue and $244.7 million earnings by 2028. This requires 52.8% yearly revenue growth and about a $193.5 million earnings increase from $51.2 million today.

Uncover how CorMedix's forecasts yield a $19.00 fair value, a 62% upside to its current price.

Exploring Other Perspectives

Eight fair value estimates from the Simply Wall St Community span roughly US$7.48 to US$63.07 per share, underlining how far apart views on CorMedix’s earnings power can be. Set against this wide dispersion, the central concern many will weigh is whether integration of the Melinta acquisition and the associated leverage truly support the kind of sustained performance implied by the more optimistic forecasts, or if those same factors could constrain the business over time.

Explore 8 other fair value estimates on CorMedix - why the stock might be worth over 5x more than the current price!

Build Your Own CorMedix Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your CorMedix research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free CorMedix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CorMedix's overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 37 best rare earth metal stocks of the very few that mine this essential strategic resource.
• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.